Hereditary ovarian cancer in Ashkenazi Jews

Familial Cancer

Volumn 3, Issue 3-4, 2004, Pages 259-264

  Robles Díaz, Luis ^a   Goldfrank, Deborah ^a   Kauff, Noah ^a   Robson, Mark ^a   Offit, Kenneth ^a  

^a Clinical Genetics Service   (United States)

Author keywords

Ashkenazi; BRCA mutation; BRCA1; BRCA2; genetic cancer predisposition; HNPCC; ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; HORMONE; ORAL CONTRACEPTIVE AGENT;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; DRUG EFFECT; FAMILIAL CANCER; GENE DELETION; GENE MUTATION; GENETIC PREDISPOSITION; HETEROZYGOTE; HUMAN; JEW; OVARY CANCER; PENETRANCE; PRIORITY JOURNAL; RISK REDUCTION; UTERINE TUBE LIGATION;

ADULT; AGE DISTRIBUTION; AGED; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; JEWS; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PEDIGREE; RISK ASSESSMENT; SURVIVAL ANALYSIS; UNITED STATES;

EID: 8544231421     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10689-004-9552-0     Document Type: Article

References (73)

1. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8-29.
2. Ries LAG, Eisen MP, Kosary CL et al. (eds). SEER Cancel-Statistics Review, 1973-1999. Bethesda, Maryland: National Cancer Institute 2002.
3. Hartge P, Schiffman MH, Hoover R et al. A case-control study of epithelial ovarian cancer. Am J Obstet Gynecol 1989; 161: 10-6.
4. McGowan L, Norris HJ, Hartge P et al. Risk factors in ovarian cancer. Eur J Gynaecol Oncol 1988; 9: 195-9.
5. Godard B, Foulkes WD, Provencher D et al. Risk factors for familial and sporadic ovarian cancer among French Canadians: a case-control study. Am J Obstet Gynecol 1998; 179: 403-10.
6. Brown GJ, St John DJ, Macrae FA, Aittomaki K. Cancer risk in young women at risk of hereditary nonpolyposis colorectal cancer: implications for gynecologic surveillance. Gynecol Oncol 2001; 80: 346-9.
7. Hall JM, Lee MK, Newman B et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250: 1684-9.
8. Narod SA, Feunteun J, Lynch HT et al. Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet 1991; 338: 82-3.
9. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71.
10. Struewing JP, Abeliovich D, Peretz T et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995; 11: 198-200.
11. Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-92.
12. Neuhausen S, Gilewski T, Norton L et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 1996; 13: 126-8.
13. Couch FJ, Weber BL. Mutations and poymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast cancer information core. Hum Mutat 1996; 8: 8-18.
14. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996; 14: 185-7.
15. Moslehi R, Chu W, Karlan B et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 2000; 66: 1259-72.
16. Modan B, Hartge D, Hirsch-Yechezkel G et al. Parity, oral contraceptives and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 235-40.
17. Yuan ZQ, Wong N, Foulkes WD et al. A missense mutation in both hMSH2 and APC in an Ashkenazi Jewish HNPCC kindred: implications for clinical screening. J Med Genet 1999; 36: 790-3.
18. Foulkes WD, Thiffault I, Gruber SB et al. The founder mutation MSH2*1906g->c is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. Am J Hum Genet 2002; 71: 1395-412.
19. Guillem JG, Rapaport BS, Kirchhoff T et al. A636P is associated with early-onset colon cancer in Ashkenazi Jews. J Am Coll Surg 2003; 196: 222-5.
20. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three US population-based case-control studies of ovarian cancer. Am J Hum Genet 1997; 60: 496-504.
21. Rubin SC. BRCA-related ovarian carcinoma. Cancer 2003; 97: 2127-9.
22. Hartge P, Struewing JP, Wacholder S et al. The Prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 1999; 64: 963-70.
23. Kauff N, Perez-Segura P, Robson M et al. Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. J Med Genet 2002; 39: 611-4.
24. Frank TS, Deffenbaugh AM, Reid JE et al. Clinical chracteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002; 20: 1480-90.
25. Ford D, Easton DF, Bishop DT et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994; 343: 692-5.
26. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995; 56: 265-71.
27. Antoniou AC, Gayther SA, Stratton JF et al. Risk models for familial breast and ovarian cancer. Genet Epidemiol 2000; 18: 173-90
28. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62: 676-89.
29. Begg C. On the use of familial aggregation in population-based case probands for calculating penetrance. JNCI 2002; 94: 1221-6.
30. [No authors listed]. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer 2000; 83: 1301-8.
31. Risch HA, McLaughlin JR, Cole DE et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68: 700-10.
32. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-30.
33. Satagopan JM, Boyd J, Kauff N et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 2002; 8: 3776-81.
34. King MC, Marks JH, Mandell JB et al. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302: 643-6.
35. Gayther SA, Warren W, Mazoyer S et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 1995; 11: 428-33.
36. Thompson D, Easton D. Breast Cancer Linkage Consortium. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 2002; 11: 329-36.
37. Brose MS, Rebbeck TR, Calzone KA et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. JNCI 2002; 94: 1365-72.
38. Thompson D, Easton D. Breast Cancer Linkage Consortium. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001; 68: 410-9.
39. Narod SA. Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer 2002; 3: 113-23.
40. Dagan E, Friedman E, Paperna T et al. Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype. Eur J Hum Genet 2002; 10: 724-8.
41. Levine DA, Boyd J. The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series. Cancer Res 2001; 61: 908-11.
42. Rebbeck TR, Wang Y, Kantoff PW et al. Modification of BRCA1-and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res 2001; 61: 5420-4.
43. Levy-Lahad E, Lahad A, Eisenberg S et al. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci USA 2001; 98: 3232-6.
44. Struewing JP et al. A single nucleotide polymorphism in the 5′UTR of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2001; 10: 955-960.
45. Phelan CM, Rebbeck TR, Weber BL et al. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet 1996; 12: 309-11.
46. Narod SA, Goldgar D, Cannon-Albright L et al. Risk modifiers in carriers of BRCA1 mutations. Int J Cancer 1995; 64: 394-8.
47. Boyd J, Sonoda Y, Federici MG et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283: 2260-5.
48. Rubin SC, Benjamin I, Behbakht K et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996; 335: 1413-6.
49. Ben David Y, Chetrit A, Hirsch-Yechezkel G et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 2002; 20: 463-6.
50. Cass I, Baldwin, RL, Varkey T et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003; 97: 2187-95.
51. Kvale G, Heuch I, Nilssen S, Beral V. Reproductive factors and risk of ovarian cancer: a prospective study. Int J Cancer 1988; 42: 246-51.
52. Wu ML, Whittmore AS, Paffengarger RS et al. Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use. Am J Epidemiol 1988; 128: 1216-27.
53. Adami HO, Hsieh CC, Lambe M et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet 1994; 344: 1250-4.
54. Gwinn ML, Lee NC, Rhodes PH et al. Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol 1990; 43: 559-68.
55. Rosenberg L, Shapiro S, Slone D et al. The WHO Collaborative Study of Neoplasia and Steroid contraceptives. Epithelial ovarian cancer and combined oral contraceptives. Int J Epidemiol 1987; 18: 538-45.
56. La Vecchia C, Decarli A, Franceschi S et al. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. Cancer Epidemiol Biomarkers Prev 1996; 5: 933-5.
57. Modugno F, Moslehi R, Ness RB et al. Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States). Cancer Causes & Control 2003; 14: 439-46.
58. Hankinson SE, Hunter DJ, Colditz GA et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. JAMA 1993; 270: 2813-8.
59. Narod SA, Sun P, Ghadirian P et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 2001; 357: 1467-70.
60. Whittemore AS, Harris R, Itnyre J. Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 1992; 136: 1184-203.
61. Franceschi S, Parazzinai F, Negri E et al. Pooled analysis of 3 European case-control studies of epithelial ovarian cancer. III. Oral contraceptive use. Int J Cancer 1991; 49: 61-5.
62. Narod SA, Risch H, Moslehi R et al. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 1998; 339: 424-8.
63. Narod SA, Sun P, Risch HA. Ovarian cancer, oral contraceptives, and BRCA mutations. N Engl J Med 2001; 345: 1706-7.
64. Ursin G, Henderson BE, Haile RW et al. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res 1997; 57: 3678-81.
65. Grabrick DM, Hartmann LC, Cerhan JR et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA 2000; 284: 1791-8.
66. Kauff N, Satagopan JM, Robson ME et al. Risk reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 1609-15.
67. Rebbeck TR, Lynch HT, Neuhausen SL et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346: 1616-22.
68. Rutter JL, Wacholder S, Chetrit A et al. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. JNCI 2003; 95: 1072-8.
69. Narod SA, Dube MP, Klijn J et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. JNCI 2002; 94(23): 1773-9.
70. Hirsh-Yechezkel G, Chetrit A, Lubin F et al. Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in Israel. Gynecol Oncol 2003; 89: 494-8.
71. [No authors listed]. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase. Lyon, France, 2001.
72. Steinberg KK, Pernarelli JM, Marcus M et al. Increased risk for familial ovarian cancer among Jewish women: a population-based case-control study. Genet Epidemiol 15: 51-9.
73. Simard J, Tonin P, Durocher F et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nature Genet 1994; 8: 392-8.